GW Pharmaceuticals (NASDAQ:GWPH) Lifted to Sell at BidaskClub

Last updated on Thursday, January 7, 2021 | 2021 MarketBeat

GW Pharmaceuticals (NASDAQ:GWPH) was upgraded by research analysts at BidaskClub from a "strong sell" rating to a "sell" rating in a research report issued to clients and investors on Thursday, BidAskClub reports.

A number of other research analysts have also recently weighed in on the stock. Cantor Fitzgerald reduced their price target on shares of GW Pharmaceuticals from $165.00 to $147.00 and set an "overweight" rating on the stock in a research report on Tuesday, December 29th. Zacks Investment Research cut shares of GW Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Tuesday. Finally, HC Wainwright reissued a "buy" rating on shares of GW Pharmaceuticals in a research report on Wednesday, November 4th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and nine have issued a buy rating to the company's stock. GW Pharmaceuticals has an average rating of "Hold" and a consensus price target of $183.08.

Shares of GWPH stock opened at $119.72 on Thursday. The stock has a market cap of $3.72 billion, a price-to-earnings ratio of -69.60 and a beta of 2.25. The company has a quick ratio of 4.31, a current ratio of 5.13 and a debt-to-equity ratio of 0.01. GW Pharmaceuticals has a fifty-two week low of $67.98 and a fifty-two week high of $144.00. The firm's 50 day moving average price is $123.36 and its two-hundred day moving average price is $114.22.

GW Pharmaceuticals (NASDAQ:GWPH) last announced its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.63) by $0.27. The firm had revenue of $137.10 million for the quarter, compared to analysts' expectations of $97.66 million. GW Pharmaceuticals had a negative net margin of 11.05% and a negative return on equity of 7.46%. GW Pharmaceuticals's revenue was up 50.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.04) earnings per share. On average, equities analysts forecast that GW Pharmaceuticals will post -1.71 EPS for the current fiscal year.

In other GW Pharmaceuticals news, CEO Justin D. Gover sold 7,200 shares of the business's stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $10.00, for a total transaction of $72,000.00. Following the sale, the chief executive officer now owns 459,653 shares in the company, valued at approximately $4,596,530. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Chairman Geoffrey W. Dr Guy sold 480,000 shares of the business's stock in a transaction dated Monday, December 7th. The stock was sold at an average price of $11.00, for a total value of $5,280,000.00. Following the sale, the chairman now owns 5,421,925 shares in the company, valued at approximately $59,641,175. The disclosure for this sale can be found here. Insiders sold 980,832 shares of company stock valued at $9,901,832 in the last ninety days. Corporate insiders own 3.10% of the company's stock.

Large investors have recently added to or reduced their stakes in the stock. First Horizon Advisors Inc. increased its holdings in GW Pharmaceuticals by 317.5% in the third quarter. First Horizon Advisors Inc. now owns 263 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 200 shares during the last quarter. FNY Investment Advisers LLC acquired a new position in shares of GW Pharmaceuticals in the third quarter valued at $33,000. Fifth Third Bancorp raised its stake in GW Pharmaceuticals by 18.9% during the third quarter. Fifth Third Bancorp now owns 1,027 shares of the biopharmaceutical company's stock worth $100,000 after acquiring an additional 163 shares in the last quarter. SG Americas Securities LLC acquired a new position in GW Pharmaceuticals during the third quarter worth $139,000. Finally, Pinnacle Associates Ltd. acquired a new stake in shares of GW Pharmaceuticals in the second quarter valued at $266,000. Hedge funds and other institutional investors own 76.43% of the company's stock.

GW Pharmaceuticals Company Profile

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, Dravet syndrome, and Lennox-Gastaut syndrome, as well as in phase III clinical trials for the treatment of tuberous sclerosis complex.

Read More: How do CD ladders protect against rising interest rates?

Analyst Recommendations for GW Pharmaceuticals (NASDAQ:GWPH)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: What is an overbought condition?



7 Sports Betting Stocks That Will Shine Beyond March Madness

One of the many consequences of the novel coronavirus was the shutdown of live sports. For sports-minded individuals, one of the events that were missed the most was the NCAA Basketball Tournament affectionately known as March Madness.

But in addition to missing the entertainment that sports provide, cities and states realized, if they didn’t already, that sports are an economic necessity.

Live sports may also be a key to their post-pandemic future. But this goes beyond hotels and restaurants.

Sports betting has become big business. Currently, 25 states and the District of Columbia have legalized sports betting either by statute or by ballot initiative. That list is likely to grow. Many states face budget deficits and want to legalize sports betting for the revenue that it could receive.

And this is about more than allowing gamblers to place bets via a sportsbook in a casino. The real driver for this is mobile sports betting. According to the American Gaming Association, over 47 million people are expected to place bets during the NCAA basketball tournament, with approximately one-third of those bets (17.8 million) being placed online.

To help you take advantage of this still-emerging trend, we’ve put together this special presentation. Here we’ll highlight seven sports betting stocks that should generate significant revenue during March Madness and beyond.

View the "7 Sports Betting Stocks That Will Shine Beyond March Madness".


Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.